201 related articles for article (PubMed ID: 1576056)
1. Formation of biologically active 13,14-dihydro-prostaglandin E1 during intravenous infusion of prostaglandin E1 in newborns with ductus arteriosus-dependent congenital heart disease.
Leonhardt A; Schweer H; Wolf D; Seyberth HW
Br J Clin Pharmacol; 1992 Mar; 33(3):323-5. PubMed ID: 1576056
[TBL] [Abstract][Full Text] [Related]
2. Formation of 13,14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease.
Peskar BA; Hesse WH; Rogatti W; Diehm C; Rudofsky G; Schweer H; Seyberth HW
Prostaglandins; 1991 Mar; 41(3):225-8. PubMed ID: 1852896
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologically active levels of PGE1 in neonates with congenital heart disease.
Leonhardt A; Kühl PG; Schweer H; Wolf D; Seyberth HW
Acta Paediatr Scand; 1989 Nov; 78(6):853-7. PubMed ID: 2603710
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects.
Cawello W; Schweer H; Müller R; Bonn R; Seyberth HW
Eur J Clin Pharmacol; 1994; 46(3):275-7. PubMed ID: 8070511
[TBL] [Abstract][Full Text] [Related]
5. In vivo formation of prostaglandin E1 and prostaglandin E2 in atopic dermatitis.
Leonhardt A; Krauss M; Gieler U; Schweer H; Happle R; Seyberth HW
Br J Dermatol; 1997 Mar; 136(3):337-40. PubMed ID: 9115911
[TBL] [Abstract][Full Text] [Related]
6. Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation.
Huang FK; Lin CC; Huang TC; Weng KP; Liu PY; Chen YY; Wang HP; Ger LP; Hsieh KS
Pediatr Neonatol; 2013 Apr; 54(2):102-6. PubMed ID: 23590954
[TBL] [Abstract][Full Text] [Related]
7. Oral prostaglandin E1 derivative (OP-1206) in an infant with double outlet right ventricle and pulmonary stenosis. Effect on ductus-dependent pulmonary circulation.
Saji T; Matsuura H; Hoshino K; Yamamoto S; Ishikita T; Matsuo N
Jpn Heart J; 1991 Sep; 32(5):735-40. PubMed ID: 1774835
[TBL] [Abstract][Full Text] [Related]
8. Effect of Long-term Administration of Prostaglandin E
Iwaki R; Matsuhisa H; Minamisawa S; Akaike T; Hoshino M; Yagi N; Morita K; Shinohara G; Kaneko Y; Yoshitake S; Takahashi M; Tsukube T; Oshima Y
Ann Thorac Surg; 2020 Dec; 110(6):2088-2095. PubMed ID: 32246933
[TBL] [Abstract][Full Text] [Related]
9. [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].
Hesse WH; Rudofsky G; Peskar BA
Wien Klin Wochenschr; 1991; 103(18):554-7. PubMed ID: 1750222
[TBL] [Abstract][Full Text] [Related]
10. On the metabolism of prostaglandin E1 administered intravenously to human volunteers.
Peskar BA; Cawello W; Rogatti W; Rudofsky G
J Physiol Pharmacol; 1991 Sep; 42(3):327-31. PubMed ID: 1793892
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E1 in infants with congenital heart disease: Indian experience.
Saxena A; Sharma M; Kothari SS; Juneja R; Reddy SC; Sharma R; Bhan A; Venugopal P
Indian Pediatr; 1998 Nov; 35(11):1063-9. PubMed ID: 10216540
[TBL] [Abstract][Full Text] [Related]
12. Determination of prostaglandin E1 and its main plasma metabolites 15-keto-prostaglandin E0 and prostaglandin E0 by gas chromatography/negative ion chemical ionization triple-stage quadrupole mass spectrometry.
Schweer H; Meese CO; Watzer B; Seyberth HW
Biol Mass Spectrom; 1994 Mar; 23(3):165-70. PubMed ID: 8148408
[TBL] [Abstract][Full Text] [Related]
13. Nursing care of the neonate receiving prostaglandin E1 therapy.
Rikard DH
Neonatal Netw; 1993 Jun; 12(4):17-22. PubMed ID: 8510622
[TBL] [Abstract][Full Text] [Related]
14. Vasodilating effect and tissue accumulation of prostaglandin E1 incorporated in lipid microspheres on the rat ductus arteriosus.
Chino Y; Minagawa T; Kohno Y; Fukushima K; Momma K
Jpn J Pharmacol; 1999 Sep; 81(1):107-14. PubMed ID: 10580378
[TBL] [Abstract][Full Text] [Related]
15. Effects of prostaglandin E1 infusion in the pre-operative management of critical congenital heart disease.
Ohara T; Ogata H; Fujiyama J; Murata Y; Abe J; Kakuta K; Hayamizu S; Kameyama S; Yoshida Y
Tohoku J Exp Med; 1985 Jun; 146(2):237-49. PubMed ID: 4040664
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E1: first stage palliation in neonates with congenital cardiac defects.
Reddy SC; Saxena A
Indian J Pediatr; 1998; 65(2):211-6. PubMed ID: 10771966
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin E1 treatment of congenital heart disease: use prior to neonatal transport.
Buck ML
DICP; 1991 Apr; 25(4):408-9. PubMed ID: 1926911
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E1 treatment in patent ductus arteriosus dependent congenital heart defects.
Tálosi G; Katona M; Rácz K; Kertész E; Onozó B; Túri S
J Perinat Med; 2004; 32(4):368-74. PubMed ID: 15346826
[TBL] [Abstract][Full Text] [Related]
19. Pseudo-Bartter syndrome in a neonate on prostaglandin infusion.
Vanhaesebrouck S; Allegaert K; Vanhole C; Devlieger H; Gewillig M; Proesmans W
Eur J Pediatr; 2003 Sep; 162(9):569-71. PubMed ID: 12811550
[TBL] [Abstract][Full Text] [Related]
20. Case report 701: Prostaglandin E1 (PGE1) periostitis.
Rowley RF; Lawson JP
Skeletal Radiol; 1991; 20(8):617-9. PubMed ID: 1776031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
